Teladoc Health, Inc. (TDOC) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)

In a discussion at the Goldman Sachs Annual Global Healthcare Conference, Teladoc CEO Charles Divita outlined the company's strategic priorities, focusing on integrated care in the U.S., leveraging its mental health position, international expansion, and operational excellence; key initiatives include unifying clinical capabilities, enhancing data-driven engagement, and shifting BetterHelp towards benefits coverage to improve conversion rates. Divita acknowledged a topline headwind from the shift to utilization-based models but emphasized growth opportunities through increased service penetration and international markets, while CFO Mala Murthy highlighted efforts to drive revenue per member and maintain disciplined cost management, including recent debt paydown and streamlining the organization.

Analysis

Teladoc Health's CEO, Charles Divita, speaking at the Goldman Sachs Global Healthcare Conference on June 11, 2025, detailed a strategic repositioning one year into his tenure, emphasizing a shift towards sustainable growth after addressing initial challenges, including the prior withdrawal and subsequent reinstatement of guidance for its BetterHelp segment. The company's refined strategy focuses on four key pillars: firstly, enhancing U.S. Integrated Care by unifying clinical capabilities and leveraging data to drive greater value for its over 100 million members and 1 million chronic condition program participants, aiming to deepen service penetration. Secondly, scaling its mental health offerings by transitioning BetterHelp towards benefits coverage to improve conversion from its 4 million annual sign-ups, where an 80% drop-off due to out-of-pocket costs currently occurs; a mere 1% net increase in conversion is cited as potentially generating $40 million in revenue. Thirdly, accelerating international expansion, which accounts for approximately 15% of Integrated Care revenue and is targeted for over 50% growth in the coming years through partnerships with public health systems and global employers. Lastly, pursuing operational excellence via cost optimization (e.g., in technology development, administrative costs, stock-based compensation) and strategic investments, such as the 'Teladoc Health Prism' care delivery platform. A significant market dynamic impacting Teladoc is the ongoing transition from subscription to utilization-based payment models, which has been a topline headwind for the U.S. Integrated Care business despite underlying growth in visits and service usage; this shift is reportedly moderating. Recent acquisitions, UpLift (for BetterHelp insurance integration) and Catapult (for preventative care and engagement), are positioned as crucial to this strategy. While Teladoc has previously demonstrated cost discipline leading to adjusted EBITDA margin improvements, current investments and acquisitions like Catapult are causing a near-term modest dilution, with management indicating a commitment to self-fund these initiatives and provide clearer financial trajectory updates in subsequent quarters. Current visit utilization rates remain in the mid-to-high single digits, suggesting considerable runway for increasing engagement within the existing member base.

Key Decisions for Investors

• Investors should closely monitor Teladoc's execution on shifting BetterHelp to an insurance-based model and increasing service penetration within its U.S. Integrated Care member base, as these are critical for reigniting topline growth amidst the transition to utilization-based revenue.
• Evaluate the progress of Teladoc's international expansion, targeting over 50% growth, and its ability to translate increased member engagement and broader service offerings into higher revenue per member.
• Assess the impact of recent M&A and strategic investments on both revenue trajectory and adjusted EBITDA margins, looking for clear evidence of synergies and a path to sustained profitability as outlined in future company updates.